000290332 001__ 290332
000290332 005__ 20250820105511.0
000290332 0247_ $$2doi$$a10.1016/j.ijbiomac.2024.132468
000290332 0247_ $$2pmid$$apmid:38761900
000290332 0247_ $$2ISSN$$a0141-8130
000290332 0247_ $$2ISSN$$a1879-0003
000290332 0247_ $$2altmetric$$aaltmetric:163519140
000290332 037__ $$aDKFZ-2024-01060
000290332 041__ $$aEnglish
000290332 082__ $$a570
000290332 1001_ $$aTang, Kang$$b0
000290332 245__ $$aNetwork-based approach for drug repurposing against mpox.
000290332 260__ $$aNew York, NY [u.a.]$$bElsevier$$c2024
000290332 3367_ $$2DRIVER$$aarticle
000290332 3367_ $$2DataCite$$aOutput Types/Journal article
000290332 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1716358302_7220
000290332 3367_ $$2BibTeX$$aARTICLE
000290332 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000290332 3367_ $$00$$2EndNote$$aJournal Article
000290332 520__ $$aThe current outbreak of mpox presents a significant threat to the global community. However, the lack of mpox-specific drugs necessitates the identification of additional candidates for clinical trials. In this study, a network medicine framework was used to investigate poxviruses-human interactions to identify potential drugs effective against the mpox virus (MPXV). The results indicated that poxviruses preferentially target hubs on the human interactome, and that these virally-targeted proteins (VTPs) tend to aggregate together within specific modules. Comorbidity analysis revealed that mpox is closely related to immune system diseases. Based on predicted drug-target interactions, 268 drugs were identified using the network proximity approach, among which 23 drugs displaying the least side-effects and significant proximity to MPXV were selected as the final candidates. Lastly, specific drugs were explored based on VTPs, differentially expressed proteins, and intermediate nodes, corresponding to different categories. These findings provide novel insights that can contribute to a deeper understanding of the pathogenesis of MPXV and development of ready-to-use treatment strategies based on drug repurposing.
000290332 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000290332 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000290332 650_7 $$2Other$$aComorbidity
000290332 650_7 $$2Other$$aDrug repurposing
000290332 650_7 $$2Other$$aMpox
000290332 650_7 $$2Other$$aVirushost interaction
000290332 7001_ $$aSun, Qianru$$b1
000290332 7001_ $$aZeng, Jinfeng$$b2
000290332 7001_ $$aTang, Jing$$b3
000290332 7001_ $$aCheng, Peiwen$$b4
000290332 7001_ $$0P:(DE-He78)58621186eeeae8ff31a0431a353c128f$$aQiu, Zekai$$b5$$udkfz
000290332 7001_ $$aLong, Haoyu$$b6
000290332 7001_ $$aChen, Yilin$$b7
000290332 7001_ $$aZhang, Chi$$b8
000290332 7001_ $$aWei, Jie$$b9
000290332 7001_ $$aQiu, Xiaoping$$b10
000290332 7001_ $$aJiang, Guozhi$$b11
000290332 7001_ $$aFang, Qianglin$$b12
000290332 7001_ $$aSun, Litao$$b13
000290332 7001_ $$aSun, Caijun$$b14
000290332 7001_ $$aDu, Xiangjun$$b15
000290332 773__ $$0PERI:(DE-600)1483284-7$$a10.1016/j.ijbiomac.2024.132468$$gVol. 270, no. Pt 2, p. 132468 -$$nPt 2$$p132468$$tInternational journal of biological macromolecules$$v270$$x0141-8130$$y2024
000290332 8564_ $$uhttps://inrepo02.dkfz.de/record/290332/files/1-s2.0-S0141813024032732-main.pdf
000290332 8564_ $$uhttps://inrepo02.dkfz.de/record/290332/files/1-s2.0-S0141813024032732-main.pdf?subformat=pdfa$$xpdfa
000290332 909CO $$ooai:inrepo02.dkfz.de:290332$$pVDB
000290332 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)58621186eeeae8ff31a0431a353c128f$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000290332 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000290332 9141_ $$y2024
000290332 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000290332 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J BIOL MACROMOL : 2022$$d2023-10-21
000290332 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000290332 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000290332 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000290332 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000290332 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000290332 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000290332 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000290332 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000290332 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000290332 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000290332 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000290332 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J BIOL MACROMOL : 2022$$d2023-10-21
000290332 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x0
000290332 980__ $$ajournal
000290332 980__ $$aVDB
000290332 980__ $$aI:(DE-He78)E055-20160331
000290332 980__ $$aUNRESTRICTED